Mark Levick is the CEO of Alvotech. Before joining the Company, he worked as the global head of development of Sandoz Biopharmaceuticals (a business unit of Novartis) since 2016. During this time, Mark oversaw the successful approval of biosimilar medicines in major markets, taking Sandoz to the industry-leading position with a total of eight approved biosimilar products. Previously Mark also held roles of increasing responsibility at Novartis in the USA and Switzerland, including the head of biologics, clinical development and respiratory development, and played a pivotal role in the approval of innovative biopharmaceutical medicines. Prior to Novartis, Mark held leadership roles in biopharmaceutical development at GlaxoSmithKline in the UK and USA and served as a medical reviewer at the UK’s Medicines and Healthcare Products Regulatory Agency and European Medicines Agency.
Before joining the industry, Mark held positions as a specialist clinician in teaching hospitals in the UK and Australia. He was awarded his medical degree from the University of Newcastle, Australia, and studied at the University of Cambridge in the UK as a Commonwealth scholar. He holds a PhD in vaccine development from Cambridge University, and is a fellow of the Royal College of Pathologists of Australasia and the Australasian College of Tropical Medicine.